Want to see IN:NURECA full AI Analyst Report?
NURECA Stock Chart & Stats
₹298.85
-₹10.75(-3.41%)
At close: 4:00 PM EST
₹298.85
-₹10.75(-3.41%)
Day’s Range― - ―
52-Week Range₹200.10 - ₹348.75
Previous CloseN/A
Volume68.50K
Average Volume (3M)9.27K
Market Cap
₹3.27B
Enterprise Value₹1.56K
Total Cash (Recent Filing)₹130.23M
Total Debt (Recent Filing)₹0.00
Price to Earnings (P/E)83.4
Beta1.24
Next Earnings
Nov 05, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)4.12
Shares Outstanding9,541,920
10 Day Avg. Volume526
30 Day Avg. Volume9,266
Financial Highlights & Ratios
PEG Ratio0.66
Price to Book (P/B)1.13
Price to Sales (P/S)1.39
P/FCF Ratio116.68
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Conservative Balance SheetVery low leverage and a large equity base provide durable financial flexibility. This reduces refinancing and solvency risk during downturns, supports investment in distribution or product development, and cushions the company while it stabilizes earnings and works to improve returns.
Improving Revenue And Profitability TrendA return to consistent profitability and renewed revenue momentum indicate the business may be exiting a volatile cycle. Sustained top-line growth and recent margin stabilization create a firmer base for reinvestment and margin expansion if management maintains execution discipline.
Home‑healthcare, At‑home Device Business ModelFocus on at‑home healthcare and wellness taps structural demand for remote care and ageing-population trends. Product mix (devices plus consumables) and direct/online distribution support scalable unit economics and cross-sell opportunities over the medium term.
Bears Say
Thin And Fragile MarginsLow operating and net margins leave limited buffer against cost inflation, pricing pressure, or sales mix shifts. Sustaining profitability will require scale, higher-margin product mix, or operating efficiency improvements; otherwise earnings remain highly sensitive to small revenue shocks.
Weak, Volatile Cash ConversionInconsistent OCF and poor FCF conversion point to working-capital swings and execution risk. The company may need ongoing cash to fund growth or inventory, limiting capacity to invest or return capital reliably until conversion stabilizes.
Low Returns On EquityROE near 1.2% signals the business is not yet generating attractive returns from its capital base. Until margins or asset efficiency improve, shareholder returns will be constrained and capital allocation choices (reinvest vs. distribution) remain limited.
Nureca Ltd. News
NURECA FAQ
What was Nureca Ltd.’s price range in the past 12 months?
Nureca Ltd. lowest stock price was ₹200.10 and its highest was ₹348.75 in the past 12 months.
What is Nureca Ltd.’s market cap?
Nureca Ltd.’s market cap is ₹3.27B.
When is Nureca Ltd.’s upcoming earnings report date?
Nureca Ltd.’s upcoming earnings report date is Nov 05, 2026 which is in 94 days.
How were Nureca Ltd.’s earnings last quarter?
Nureca Ltd. released its earnings results on Jul 21, 2026. The company reported ₹3.214 earnings per share for the quarter, beating the consensus estimate of N/A by ₹3.214.
Is Nureca Ltd. overvalued?
According to Wall Street analysts Nureca Ltd.’s price is currently Overvalued.
Does Nureca Ltd. pay dividends?
Nureca Ltd. pays a Semiannually dividend of ₹3 which represents an annual dividend yield of N/A. See more information on Nureca Ltd. dividends here
What is Nureca Ltd.’s EPS estimate?
Nureca Ltd.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Nureca Ltd. have?
Nureca Ltd. has 9,541,920 shares outstanding.
What happened to Nureca Ltd.’s price movement after its last earnings report?
Nureca Ltd. reported an EPS of ₹3.214 in its last earnings report, beating expectations of N/A. Following the earnings report the stock price went up 3.564%.
Which hedge fund is a major shareholder of Nureca Ltd.?
Currently, no hedge funds are holding shares in IN:NURECA
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Nureca Ltd.
Operating in India, Nureca Limited is a business-to-consumer (B2C) firm specializing in home healthcare and general wellness solutions. Their extensive product portfolio addresses various health needs, encompassing items for managing chronic conditions like nebulizers, blood pressure monitors, finger pulse oximeters, glucose meters, and thermometers. They also provide orthopedic aids such as massagers, pain monitoring devices, posture correctors, and rehabilitation equipment. Further offerings include humidifiers and steamers, personal weighing scales, yoga and exercise accessories, fitness trackers, and dental and personal hygiene essentials. Additionally, Nureca caters to mother and infant care with products like baby feeding accessories, carry cots, baby skincare items, and bottle warmers/sterilizers. They also supply nutritional supplements, weight management aids, and advanced monitoring devices such as ECG machines, activity trackers, and smart scales. These diverse offerings are marketed under their proprietary brands: Dr Trust, Dr Physio, and Trumom. Distribution occurs through a multi-channel approach, utilizing third-party e-commerce platforms, a network of distributors and retailers, as well as their direct-to-consumer website, drtrust.in. Established in 2016, Nureca Limited is headquartered in Chandigarh, India.
Technical Analysis
Amrutanjan Health Care Limited
―
Blue Jet Healthcare Limited
―
Procter & Gamble Health Ltd.
―
Sanofi Consumer Healthcare India Limited
―
Zota Health Care Ltd.
―